Post-trial Access in Maternal Vaccine Trials.

Area of Science:

• Clinical Ethics
• Vaccinology
• Public Health

Background:

• Post-trial access (PTA) to experimental interventions is ethically mandated before clinical trial initiation.
• While PTA is discussed in preventive vaccine research, it is often overlooked in maternal vaccine trials due to the unique considerations of pregnancy and infant health.
• Formalized international ethical guidance on PTA has existed since 2000, yet its application in maternal vaccination research remains unclear.

Purpose of the Study:

• To examine the application and adherence to post-trial access (PTA) provisions in maternal vaccine trials.
• To compare PTA practices in publications before and after 2000, when international ethical guidelines were updated.
• To assess principal investigators' awareness of PTA requirements in maternal vaccination research.

Main Methods:

• Systematic review of randomized maternal vaccine trials (Phases II and III) published before and after 2000.
• Analysis of trial publications for descriptions of PTA provisions, referencing World Medical Association's Declaration of Helsinki and CIOMS guidelines.
• Questionnaire survey sent to principal investigators of identified trials to ascertain their knowledge and implementation of PTA.

Main Results:

• No trial articles, either before or after 2000, described PTA provisions (0/7 and 0/17, respectively).
• Over half of the contacted principal investigators were unfamiliar with international PTA recommendations.
• PTA was primarily addressed by publishing trial results, and revisions to ethical guidelines in 2002 did not enhance PTA provisions in maternal vaccine trials.

Conclusions:

• There is a significant gap in the documented application and understanding of post-trial access (PTA) in maternal vaccine trials.
• Ethical guidelines and their revisions have not translated into improved PTA provisions for this specific population.
• PTA is a shared responsibility; incorporating explicit PTA provisions into maternal vaccination trial protocols and publications is essential for transparency.